Search

Displaying results 2441 - 2450 of 4590 in total
  1. Drug

    Clomipramine

    go.drugbank.com/drugs/DB01242
    ApprovedInvestigationalVet approved

    In non-depressed individuals, clomipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, clomipramine exerts a positive effect on mood.

  2. Drug

    Chlorprothixene

    go.drugbank.com/drugs/DB01239
    ApprovedInvestigationalWithdrawn

    Chlorprothixene exerts strong blocking effects by blocking the 5-HT2 D1, D2, D3, histamine H1, muscarinic and alpha1 adrenergic receptors.

  3. Drug

    Dipyridamole

    go.drugbank.com/drugs/DB00975
    ApprovedInvestigational

    A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin.

  4. Drug

    Estradiol cypionate

    go.drugbank.com/drugs/DB13954
    ApprovedVet approved

    However, after menopause, most endogenous estrogen is produced by conversion of androstenedione, secreted by the adrenal cortex, to estrone by peripheral tissues. … First-pass metabolism by the gut and the liver quickly degrades the estradiol molecule before it gets a chance to enter systemic circulation and exert its estrogenic effects [A12102].

  5. Drug

    Bordetella pertussis fimbriae 2/3 antigen

    go.drugbank.com/drugs/DB10790
    ApprovedInvestigational

    Bordetella pertussis fimbriae 2/3 antigen is a vaccine for the prophylaxis of the disease caused by Bordetella pertussis which is a a Gram-negative coccobacillus that expresses two serologically distinct

  6. Drug

    Alglucerase

    go.drugbank.com/drugs/DB00088
    ApprovedWithdrawn

    Alglucerase is prepared by modification of the oligosaccharide chains of human Beta-glucocerebrosidase. … Alglucerase was first approved by the FDA in 1991;[A254816] however, it was later discontinued from the market.

  7. Drug

    Human papillomavirus type 33 L1 capsid protein antigen

    go.drugbank.com/drugs/DB10311
    ApprovedInvestigational

    It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) type 33. … The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Type 33 which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae

  8. Drug

    Human papillomavirus type 45 L1 capsid protein antigen

    go.drugbank.com/drugs/DB10312
    ApprovedInvestigational

    It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) type 45. … The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Type 45 which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae

  9. Drug

    Human papillomavirus type 58 L1 capsid protein antigen

    go.drugbank.com/drugs/DB10314
    ApprovedInvestigational

    It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) type 58. … The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Type 58 which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae

  10. Drug

    Rucaparib

    go.drugbank.com/drugs/DB12332
    ApprovedInvestigational

    By targeting the genetically-mutated cancer cells that lack a DNA repair mechanism, rucaparib causes cancer cell death and reduces tumour growth. … [A249240] The drug was later approved by the European Commission in May 2018.[L42185] It is currently used to treat recurrent ovarian and prostate cancer in adults.[L42155,L42185].